Skip to content
Clinical Trials – home
Xenon Pharmaceuticals Inc.
Sponsor

Xenon Pharmaceuticals Inc.

3650 Gilmore Way, V5G 4W8

About the sponsor

Clinical research is centered on focal epilepsy, including adult focal (partial onset) epilepsy and focal-onset seizures, with additional attention to primary generalized tonic-clonic seizures.

  • Focal-onset seizures
  • Adult focal epilepsy
  • Primary generalized tonic-clonic seizures

These studies reflect sustained interest in seizure reduction and symptom control across multiple forms of epilepsy.

About Specializations

Xenon Pharmaceuticals Inc. runs clinical trials in conditions such as Partial seizures, Generalised tonic-clonic seizure, Major depression, Bipolar I disorder, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Bipolar I disorder

Not yet recruiting

A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Bipolar I disorder

Not yet recruiting

A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Major depression

Not yet recruiting

A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Partial seizures

Not recruiting

Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Partial seizures

Not recruiting

Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.